By Serafina Smith, Ben Brody and Ilana Kowarski (July 25, 2023) -- Following Amgen and Horizon Therapeutics’ recent counterclaim against the Federal Trade Commission alleging that the agency’s in-house court violates the Constitution, a blueprint has emerged for dealmakers to challenge the constitutionality of FTC proceedings. And with each additional challenge, the danger for the FTC will grow, as every decision a new court makes on the issue creates a potential opportunity for Supreme Court review of the agency’s authority....